Bristol Pravigard PAC
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Bristol-Myers Squibb's Pravigard PAC clears FDA June 24, making it the first aspirin co-packaged product for reducing the occurrence of serious cardiovascular events. The Pravachol (pravastatin)/buffered aspirin combo will launch in August at the same average wholesale price as Pravachol to discourage patients from purchasing the treatments separately. FDA notes Pravigard PAC's convenience and potential for increased compliance in a June 25 "Talk Paper." BMS also is developing a single tablet version of the combination (1Pharmaceutical Approvals Monthly Aug. 1, 2002, In Brief